Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Imunon, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

INVESTORS ARE REMINDED THAT SHAREHOLDERS OF RECORD AS OF AUGUST 7, 2025, WILL RECEIVE A 15% STOCK DIVIDEND PAYMENT LAWRENCEVILLE, N.J., AUG. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, EARLIER TODAY REPORTED FINANCIAL RESULTS FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2025, AND HIGHLIGHTED RECENT BUSINESS UPDATES, INCLUDING PROGRESS IN ADVANCING PHASE 3 CLINICAL DEVELOPMENT OF ITS LEAD CANDIDATE IMNN-001 IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND THE INTRODUCTION OF A 15% STOCK DIVIDEND PAYMENT TO SHAREHOLDERS.

IMUNON RECAPS HIGHLIGHTS FROM 2025 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL

STOCK DIVIDEND ISSUED TO IMUNON SHAREHOLDERS REFLECTS CONFIDENCE IN CLINICAL PROGRAMS, LONG-TERM GROWTH STRATEGY AND DEDICATION TO REWARDING SHAREHOLDERS FIRST PATIENT DOSED IN PHASE 3 OVATION 3 STUDY OF IMNN-001 FOR TREATMENT OF NEWLY DIAGNOSED ADVANCED OVARIAN CANCER COMPANY TO HOLD CONFERENCE CALL TODAY AT 11:00 A.M. ET LAWRENCEVILLE, N.J.

IMUNON REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

INITIATION OF ADDITIONAL TRIAL SITES AND PATIENT ENROLLMENT ACTIVITIES ONGOING WITH MULTIPLE PATIENTS IN SCREENING LAWRENCEVILLE, N.J., JULY 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT OF ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PIVOTAL PHASE 3 OVATION 3 STUDY EVALUATING THE COMPANY'S LEAD CANDIDATE, IMNN-001, FOR THE TREATMENT OF WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER.

IMUNON ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 OVATION 3 STUDY OF IMNN-001 IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER

LAWRENCEVILLE, N.J., JULY 29, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN LATE-STAGE DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, ANNOUNCES THAT THE COMPANY WILL HOST A CONFERENCE CALL AT 11:00 A.M. ET ON TUESDAY, AUGUST 5, 2025 TO DISCUSS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND PROVIDE AN UPDATE ON ITS CLINICAL DEVELOPMENT PROGRAM WITH IMNN-001, A DNA-BASED INTERLEUKIN-12 (IL-12) IMMUNOTHERAPY, INCLUDING PROGRESS IN ADVANCING THE IMNN-001 DEVELOPMENT PROGRAM IN A PHASE 3 CLINICAL TRIAL IN ADVANCED OVARIAN CANCER.

IMUNON TO HOLD SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE CONFERENCE CALL ON TUESDAY, AUGUST 5, 2025

STOCK DIVIDEND REFLECTS COMPANY'S CONFIDENCE IN ITS PHASE 3 STUDY, LONG-TERM GROWTH POTENTIAL, AND DEDICATION TO SHAREHOLDERS

IMUNON ANNOUNCES STOCK DIVIDEND BOOSTING SHAREHOLDER VALUE

LAWRENCEVILLE, N.J., JULY 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT OF ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED A REVERSE STOCK SPLIT OF ITS ISSUED AND OUTSTANDING COMMON STOCK, PAR VALUE $0.01 PER SHARE, AT A RATIO OF ONE (1) SHARE OF COMMON STOCK FOR EVERY FIFTEEN (15) SHARES OF COMMON STOCK, THAT WILL BECOME EFFECTIVE AS OF 12:01 A.M. (EASTERN TIME) ON JULY 25, 2025 (THE EFFECTIVE DATE). THE COMPANY'S COMMON STOCK WILL BEGIN TRADING ON A SPLIT-ADJUSTED BASIS WHEN THE MARKET OPENS ON JULY 25, 2025. AT THE COMPANY'S ANNUAL MEETING OF STOCKHOLDERS HELD ON JULY 11, 2025, THE COMPANY'S STOCKHOLDERS APPROVED A PROPOSAL TO AUTHORIZE A REVERSE STOCK SPLIT OF THE COMPANY'S COMMON STOCK, AT A RATIO WITHIN THE RANGE OF 1-FOR-5 TO 1-FOR-18. THE COMPANY'S BOARD OF DIRECTORS APPROVED A 1-FOR-15 REVERSE SPLIT RATIO, AND ON JULY 21, 2025, THE COMPANY FILED A CERTIFICATE OF AMENDMENT TO ITS AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT THE REVERSE STOCK SPLIT EFFECTIVE JULY 25, 2025. THE COMPANY'S COMMON STOCK WILL CONTINUE TO TRADE ON THE NASDAQ CAPITAL MARKET UNDER THE STOCK TICKER IMNN BUT WILL TRADE UNDER THE NEW CUSIP NUMBER 15117N701.

IMUNON ANNOUNCES REVERSE STOCK SPLIT

MANAGEMENT PROVIDES NASDAQ HEARING PANEL WITH A COMPREHENSIVE EXECUTABLE PLAN FOR LONG TERM COMPLIANCE LAWRENCEVILLE, N.J., JULY 15, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT OF ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE NASDAQ HEARING PANEL HAS GRANTED ITS REQUEST FOR AN EXCEPTION TO COMPLETE ITS COMPLIANCE PLAN, ALLOWING THE COMPANY TO MAINTAIN ITS LISTING ON THE NASDAQ STOCK MARKET.

IMUNON GRANTED CONTINUED LISTING EXTENSION BY NASDAQ TO COMPLETE COMPLIANCE PLAN

ASCO 2025 OVERALL SURVIVAL DATA BOLSTER IMNN-001'S POTENTIAL IN ADVANCED OVARIAN CANCER, SUPPORTED BY ROBUST TRANSLATIONAL RESULTS AT ESMO

IMUNON PRESENTS POSITIVE PHASE 2 TRANSLATIONAL DATA OF IMNN-001 IN ADVANCED OVARIAN CANCER AT ESMO GYNAECOLOGICAL CANCERS CONGRESS 2025

CLINICAL DATA HIGHLIGHT PLACCINE'S SIX-MONTH DURABILITY, TEMPERATURE STABILITY, AND MANUFACTURING ADVANTAGES OVER MRNA VACCINES

IMUNON ANNOUNCES PLACCINE DNA VACCINE TECHNOLOGY ABSTRACT SELECTED FOR ORAL PRESENTATION AT 10TH INTERNATIONAL CONFERENCE ON VACCINES RESEARCH & DEVELOPMENT

CONSISTENT OS EFFICACY BENEFIT ACROSS MULTIPLE TREATMENT SUBGROUPS DEMONSTRATES IMNN-001'S ABILITY TO RECRUIT A POWERFUL ANTI-CANCER IMMUNE RESPONSE

Imunon, Inc.

IMNN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Imunon, Inc.

IMNN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMNN